This video has been created and funded by Biogen. This information is intended for healthcare professionals in the EU. The presented content is based on the omaveloxolone EMA approved label.
Prescribing Information: SKYCLARYS™️ (omaveloxalone) is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.1
| ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. |
Watch this video recording of Biogen’s satellite symposium at EAN 2024 (Helsinki, Finland), entitled ‘Friedreich Ataxia: Reshaping the Disease Course’, with esteemed speakers Mathieu Anheim (Strasbourg, France) and Jörg Schulz (Aachen, Germany).
Anheim discusses recognising the early signs and symptoms of Friedreich Ataxia (FA) using patient examples, and the importance of genetic testing to confirm FA diagnosis. He also presents the patient journey and burden of disease, and how to assess disease progression.
Schulz presents the management of patients with FA and the treatment options available for these patients. He highlights the importance of having a multidisciplinary team to adequately treat patients, especially in a multi-factorial disease such as FA. Until recently, there were no pharmacological treatments available for FA. Schulz explains the mechanism of action of omaveloxolone, currently the only European Medicines Agency (EMA) and U.S Food and Drug Administration (FDA) approved treatment for FA; data from the MOXIe clinical trial programme of potentially available treatments.
Chapters
- 00:00 – 08:29 – Introduction & Welcome
- 08:29 – 29:50 – Mathieu Anheim on Pinpointing the Signs and Symptoms for Early Diagnosis (Patients gave informed, written consent for video recordings and to the use of the video recordings)
- 29:50 – 49:56 – Jörg Schulz on Targeting the Underlying Mechanism of Disease
Speakers:
Mihaela Vlaicu (Chair), Head of Medical, Europe, Biogen
Mathieu Anheim, Professor of Neurology, Movement Disorders Unit, University Hospital of Strasbourg, France
Jörg Schulz, Professor of Neurology and Chair of the Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany
Disclosures: Vlaicu is a Biogen employee and receives salary and stock from Biogen. Anheim declares honoraria from Biogen, Reata Pharmaceuticals, AbbVie, Merz, Orkyn, Linde, Aguettant, Linde, Ipsen, Asdia, Ever Pharma, Teva. Schulz declares honoraria from Merz, Teva, Bayer, UCB, Lilly, Boehringer, GSK, Bial, Novartis, Biogen, Eisai; research support from Biogen, Eisai, Lilly; and has acted as an advisor/consultant for Forward Pharma, MSD, Lundbeck, Biogen, Eisai, Novo Nordisk, Roche, Reata, Lilly.
Disclaimer: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Reference
-
Reata Ireland Limited. SKYCLARYS™️ (omaveloxolone). Summary of Product Characteristics. 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/skyclarys. Last accessed: 2 August 2024.
Job code: Biogen-246028
Date of prep: 22/07/2024
